Launch a Product
A Comprehensive, Customizable Life Sciences Commercialization Model
Even though pharma companies spend more than $125 million over the three years leading up to a drug’s launch, 66% of launches don’t meet expectations. Financial risk, industry pressures and unforeseen complexities are forcing developers and investors to seek advanced commercialization options that maximize their pipelines.
EVERSANA COMPLETE Commercialization®, an award-winning model that is disrupting the pharma industry, offers an alternative to selling, out-licensing or launching internally.
Launch Smarter . Maximize Value.
A Full-Scale Launch Model for Emerging Pharma
- Affords investors full access to a complete, end-to-end commercialization model
- Delivers more value than traditional licensing or launching on your own
- Activates ready-to-deploy, high-performance pharma commercial solutions and distribution engine
- Accelerates your product from early development to marketing, positively impacting patient outcomes
- Mitigates risk and combats curveballs that manufacturers cannot predict when launching products
A Customized Commercialization Model for Oncology Therapies
- Offers an integrated platform of commercialization services provides fit-for-purpose solutions to support oncology therapy commercialization
- Leverages data-driven solutions to account for smaller patient populations, evolving patient journeys and interactions with the FDA
- Maximizes and compliments existing internal resources to effectively manage go-to-market strategies
- Provides exclusive access to an established infrastructure, networks and expertise in the oncology market that may not be available in-house
A Life Cycle Management Model for Established Brands
- Eliminates capability and capacity restraints to increase the throughput of in-licensed assets
- Serves as a catalyst for biopharma companies to address the management of their established brand portfolios
Complete, full-scale, customizable infrastructure amplified by top industry launch leaders
- Optimize the launch of precommercial assets
- Capture full revenue potential through maturity
Revolutionary, nontraditional financial deal structures that provide flexibility of terms and options
- Provides an alternative to traditional and more common strategies, such as selling, out-licensing or going at it alone
- Reduces upfront cash investments necessary to launch
- Maximizes revenue potential and minimizes financial risk
Integrated, predictive and actionable data to maximize growth potential
- Maximizes the ROI of data and analytics investments
- Enhances decision-making
- Creates a seamless patient journey and positively impacts outcomes
Rewiring Commercialization for Biotech’s New Reality
New modalities, compressed timelines and smaller patient populations are creating pressures that traditional commercialization models weren’t designed to support.
EVERSANA President Greg Skalicky and Precigen President and CEO Helen Sabzevari discussed how emerging innovators can rethink commercialization to meet this moment.
Case Studies: Real-World Impact
Leveraging our data and analytics platform, our team works together to produce the best outcomes for our partners and their patients.
AGILITY
Our team is trained to proactively monitor market conditions, assess the commercial readiness of the program and course-correct in an agile manner.
SPEED
Our integrated systems and culture allow us to mobilize the execution team quickly and communicate efficiently to create a positive customer experience.
RISK MANAGEMENT
Our proven, ready-to-deploy commercialization model minimizes operational and financial risks for our partners.
Learn more about our recent partnerships.
Find out if your asset qualifies for the COMPLETE model.
Contact our team now for a complimentary assessment and fast-track your success!